02 / RESEARCH HISTORY
Development Timeline
2010–2018
Incretin research establishes GLP-1 + GIP synergy (Lilly, Novo Nordisk competing programs). GLP-1 monotherapy (semaglutide, liraglutide) demonstrates 10–15% weight loss. Dual GLP-1/GIP (tirzepatide) pushes to 20–22%. Research question: can glucagon receptor co-agonism further amplify energy expenditure?
2019–2022
Eli Lilly designs LY3437943 — a C18 fatty acid-conjugated peptide with 6-day half-life enabling once-weekly SC dosing. Triple agonism engineered with balanced receptor potency: GLP-1R (strong), GIPR (strong), GCGR (moderate — enough to boost thermogenesis without glucagon-mediated hyperglycemia).
2023 (June)
NEJM Phase II trial results: 338 participants with obesity. After 48 weeks, highest dose group (12 mg/week) achieved 24.2% mean body weight reduction. At 24 weeks, 8 mg cohort averaged 17.5% loss. Unprecedented numbers. Trial dubbed "breakthrough" by obesity medicine community. No serious adverse events beyond GI class effects.
2023–2024
Phase III trials (TRIUMPH program) initiated for obesity and T2D. Additional trials for NASH/metabolic-associated liver disease, heart failure, and CKD. Lilly projects NDA submission 2025–2026. Widely expected to surpass tirzepatide in efficacy.
2024–present
Compounded retatrutide becomes available through research chemical suppliers due to Phase II data driving physician and patient interest. Protocol development primarily extrapolated from Phase II dosing escalation scheme. No commercial product approved as of 2025.
Clinical Context: Retatrutide achieved 24.2% body weight loss in 48 weeks — the highest ever recorded in a pharmaceutical obesity trial at that time. For context: semaglutide 2.4mg (Wegovy) averages 14.9%, tirzepatide 15mg averages 22.5%. Retatrutide's glucagon component adds thermogenic amplification that the other agents lack.
04 / RECONSTITUTION
Preparation Protocol
// 30MG VIAL — STANDARD RECONSTITUTION
30,000 mcg ÷ 300 units BAC water = 100 mcg per unit
Add 3.0 mL (300 units) bacteriostatic water to 30mg lyophilized vial.
| TARGET DOSE |
UNITS TO DRAW |
VOLUME |
PHASE |
| WEEK 1–42 mg2,000 mcg |
20 units |
0.20 mL |
Initial; GI tolerance establishment |
| WEEK 5–84 mg4,000 mcg |
40 units |
0.40 mL |
Low dose escalation |
| WEEK 9–126 mg6,000 mcg |
60 units |
0.60 mL |
Mid escalation; most users plateau here |
| WEEK 13–208 mg8,000 mcg |
80 units |
0.80 mL |
Strong efficacy range; Phase II sweet spot |
| MAX12 mg12,000 mcg |
120 units |
1.20 mL |
Highest Phase II dose — 24.2% loss at 48wk |
🧊
RECONSTITUTED SHELF LIFE
30 days after mixing
Triple agonist GLP-1 — matches pharmacy BUDs. 30-day window.
Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze
Preload syringes/cartridges to minimize vial disturbance
Storage: Lyophilized powder — refrigerate (recommended), protect from light. Reconstituted: refrigerate (36–46°F / 2–8°C), use within 30 days. Once-weekly dosing means one vial = ~30 weeks at 2mg or ~3–4 weeks at 8mg.
05 / DOSING PROTOCOL
Escalation Protocol (Phase II Derived)
| WEEK |
DOSE |
UNITS |
RATIONALE |
| 1–4 |
2 mg weekly |
20u |
GI system adaptation; minimal nausea at this dose |
| 5–8 |
4 mg weekly |
40u |
First significant weight loss typically begins here |
| 9–12 |
6 mg weekly |
60u |
Escalate if GI tolerance established and progress desired |
| 13–20 |
8 mg weekly |
80u |
Strong fat loss phase; energy expenditure upregulation |
| 20+ |
8–12 mg weekly |
80–120u |
Maintain at effective dose; continue until goal achieved |
GI Management: Nausea and vomiting are the primary dose-limiting side effects — identical to semaglutide/tirzepatide class. Strategies: take weekly dose before sleep, eat small portions 3–4×/day vs. large meals, avoid high-fat/spicy foods during dose escalation weeks, stay hydrated with electrolytes.
Injection Site: Subcutaneous — abdomen, outer thigh, back of upper arm. Rotate sites weekly. No food restriction at time of injection. Once-weekly dosing on a consistent day is preferred.
08 / CYCLE PROTOCOL
Recommended Cycle
8–12
WEEKS OFF (IF CYCLING)
Phase I — Tolerance (Weeks 1–8): 2 mg/week → 4 mg/week. GI adaptation. Weight loss begins at week 4–6. Patients with prior GLP-1 experience (semaglutide/tirzepatide) may escalate faster; naive patients — take the full 4 weeks per dose level.
Phase II — Active Loss (Weeks 9–24): Escalate to 6 mg → 8 mg per protocol. Most significant weight loss phase. Expect 1–2 lbs/week. GCGR-driven thermogenesis amplifies fat loss beyond GLP-1/GIP effects alone.
Phase III — Maintenance or Maximum (Weeks 24+): At goal weight — step down to lowest effective dose (often 4–6 mg/week). Pursuing maximum loss — escalate to 12 mg if tolerated. Phase II showed continued loss to 48 weeks with no plateau at 12 mg.
Cycling Consideration: Retatrutide, like all GLP-1 class agents, results in weight regain upon discontinuation (average 50–60% of lost weight returns within 1 year). Many users treat this as a long-term maintenance medication rather than a fixed cycle. If cycling, have a robust diet/lifestyle plan in place before stopping.
Body Composition Stack: Combine with Ipamorelin/CJC-1295 (GH pulse preservation), resistance training 3×/week, and 1.6–2.0g protein/kg body weight to prevent lean mass loss during aggressive weight loss phase.
⚠ SPLIT DOSING · 2x OR 3x PER WEEK
The honest pros/cons nobody's giving you
Splitting your weekly Reta dose into 2x/week (Mon/Thu) or 3x/week (Mon/Wed/Fri) is popular — especially past 8 mg. Zero clinical trials validate it. Every NEJM result (24% weight loss, 86% liver fat reduction) used once-weekly dosing.
PK MATH — SERUM PEAK vs STEADY STATE
Weekly: 180% peak
3:1 sawtooth
2x/week: 135% peak
−25% vs weekly
3x/week: 115% peak
−36% vs weekly
✅ PROS
- Fewer GI side effects (nausea tracks peak)
- Steadier appetite suppression all 7 days
- Lower HR spike (+6-11 bpm blunted)
- Less muscle catabolism signal
- Cleaner taper in half-week steps
- Better titration granularity between ramps
🚫 CONS
- ZERO clinical trials — off-protocol
- Peaks may drive appetite effect more than AUC (smoother = possibly weaker)
- 2-3x injection burden + compliance risk
- BAC shelf life becomes bottleneck
- More vial punctures = more rubber coring
- More days to forget or double-up
🎯 DECISION MATRIX
Stay weekly IF: under 6 mg · first Reta cycle · compliance is an issue · want to match NEJM results.
Split IF: past Ramp 3 (8 mg+) and GI is limiting · cardiac history / on beta blockers · serious lifter on aggressive cut.
Split dosing requires precise half-unit accuracy. Standard insulin syringes can't hit it cleanly — the pen is the reason this protocol is viable at all. Research use only · not medical advice · consult a licensed provider.
READY TO ADD THIS TO YOUR STACK?
Drop Retatrutide into your protocol tracker — dosing pre-filled, timing set, cycle ready.
ADD TO MY PROTOCOL →
Saves your dose selection. Returns you here after.
Research Compound Notice: Retatrutide (LY3437943) is currently in Phase III clinical trials. It is not FDA-approved. Phase II data published in NEJM (2023) shows remarkable efficacy and acceptable safety profile, consistent with the GLP-1 drug class. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. GI side effects are manageable with slow dose escalation. Long-term safety data beyond 48 weeks in research settings is limited. Consult a qualified healthcare provider.
EMERGING · 2025–2026
Emerging research — cancer & inflammation
In March 2025, Nature published preclinical findings that have people paying attention. This is not clinical evidence for cancer treatment — it's early mouse-model research. But the numbers are striking enough to report.
🧬 PRECLINICAL CANCER DATA (OBESE MICE)
Pancreatic cancer: 14-fold reduction in tumor volume on retatrutide vs controls. Semaglutide alone only achieved 4-fold — Reta was ~3.5× more potent. Delayed tumor onset + attenuated engraftment.
Lung cancer: 17-fold reduction in tumor volume. 50% reduced tumor engraftment. Significantly delayed onset.
Triple-negative breast cancer (TNBC): Reta + gemcitabine overcame obesity-induced chemotherapy resistance. Mechanism: suppressed YAP oncogenic signaling via glycosylation + ubiquitylation modulation.
Proposed mechanism: Reta's triple agonism (GLP-1 + GIP + glucagon) aggressively reverses the metabolic tumor-promoting environment in obese subjects (chronic inflammation, insulin resistance, hormonal dysregulation, elevated IGF-1). Some GLP-1/GIP/glucagon receptors are also expressed on certain tumor cells, so direct anti-tumor effects are possible too.
IMPORTANT CAVEATS:
- All cancer data is preclinical (mouse models). Not human trial data.
- Retatrutide is NOT FDA-approved for cancer treatment and this is NOT medical advice.
- The medullary thyroid carcinoma (MTC) boxed warning still applies to all GLP-1 agonists including Reta — contraindicated in MEN2 and personal/family history of MTC.
- Human cancer trials for Reta haven't started — listings NCT06383390 and NCT07232719 are in planning stages.
On autoimmune disease
No direct human or preclinical studies on Retatrutide for autoimmune conditions (MS, lupus, RA, T1D, IBD). Limited GLP-1 class-level data suggests general anti-inflammatory effects (reduced hsCRP, IL-6, TNF-α) that may benefit patients with both metabolic + autoimmune conditions as a secondary effect — but GLP-1 agonists are NOT a primary therapeutic target for autoimmune disease.